BG104059A - Diabetes treatment with rosiglytazone and insulin - Google Patents

Diabetes treatment with rosiglytazone and insulin

Info

Publication number
BG104059A
BG104059A BG104059A BG10405900A BG104059A BG 104059 A BG104059 A BG 104059A BG 104059 A BG104059 A BG 104059A BG 10405900 A BG10405900 A BG 10405900A BG 104059 A BG104059 A BG 104059A
Authority
BG
Bulgaria
Prior art keywords
rosiglytazone
insulin
diabetes treatment
treatment
nontoxic
Prior art date
Application number
BG104059A
Other languages
Bulgarian (bg)
English (en)
Inventor
Stephen Smith
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of BG104059A publication Critical patent/BG104059A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG104059A 1997-06-18 2000-01-06 Diabetes treatment with rosiglytazone and insulin BG104059A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712866.4A GB9712866D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
PCT/EP1998/003692 WO1998057636A1 (en) 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin

Publications (1)

Publication Number Publication Date
BG104059A true BG104059A (en) 2000-10-31

Family

ID=10814527

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104059A BG104059A (en) 1997-06-18 2000-01-06 Diabetes treatment with rosiglytazone and insulin

Country Status (30)

Country Link
EP (1) EP0999837A1 (enrdf_load_html_response)
JP (1) JP2002504138A (enrdf_load_html_response)
KR (1) KR20010013843A (enrdf_load_html_response)
CN (1) CN1133431C (enrdf_load_html_response)
AP (1) AP1287A (enrdf_load_html_response)
AR (2) AR015894A1 (enrdf_load_html_response)
AU (1) AU8216398A (enrdf_load_html_response)
BG (1) BG104059A (enrdf_load_html_response)
BR (1) BR9810444A (enrdf_load_html_response)
CA (1) CA2294141A1 (enrdf_load_html_response)
CO (1) CO4940454A1 (enrdf_load_html_response)
DZ (1) DZ2521A1 (enrdf_load_html_response)
EA (1) EA004800B1 (enrdf_load_html_response)
GB (1) GB9712866D0 (enrdf_load_html_response)
HU (1) HUP0003260A3 (enrdf_load_html_response)
ID (1) ID23951A (enrdf_load_html_response)
IL (1) IL133143A0 (enrdf_load_html_response)
IN (1) IN189723B (enrdf_load_html_response)
MA (1) MA26511A1 (enrdf_load_html_response)
NO (1) NO996265D0 (enrdf_load_html_response)
OA (1) OA11517A (enrdf_load_html_response)
PE (1) PE104499A1 (enrdf_load_html_response)
PL (1) PL343123A1 (enrdf_load_html_response)
SK (1) SK179399A3 (enrdf_load_html_response)
TR (1) TR199903095T2 (enrdf_load_html_response)
TW (1) TW587937B (enrdf_load_html_response)
UA (1) UA70299C2 (enrdf_load_html_response)
UY (1) UY25050A1 (enrdf_load_html_response)
WO (1) WO1998057636A1 (enrdf_load_html_response)
ZA (1) ZA985237B (enrdf_load_html_response)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
ES2204557T3 (es) 1999-04-23 2004-05-01 Smithkline Beecham Plc Derivado de tiazolidindiona y su uso como antidiabetico.
ES2291210T3 (es) 1999-06-21 2008-03-01 Eli Lilly And Company Uso sinergistico de tiazolidindionas con peptido-1 tipo glucagona y sus agonistas para tratar la diabetes no insulina-dependiente.
CA2369839A1 (en) * 1999-06-25 2001-01-04 Minimed, Inc. Compositions of insulin and insulin-related peptide for treating diabetes
US6468507B1 (en) * 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
GB0023970D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
AU2002248464A1 (en) 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
US6531461B1 (en) 2001-06-04 2003-03-11 Louis Obyo Obyo Nelson Medicament for the treatment of diabetes
WO2002100396A1 (en) * 2001-06-07 2002-12-19 Wyeth COMBINATION OF A PTPase INHIBITOR AND A THIAZOLIDINEDIONE AGENT
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
PL210871B1 (pl) * 2002-11-08 2012-03-30 Hoffmann La Roche Pochodne oksazolu, sposób ich wytwarzania, środki farmaceutyczne i zastosowanie pochodnych oksazolu
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
CN102389427A (zh) * 2011-10-10 2012-03-28 成都恒瑞制药有限公司 含有罗格列酮和盐酸西替利嗪的固体口服制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3081245B2 (ja) * 1993-09-15 2000-08-28 三共株式会社 Niddmの発症を阻止又は遅延するためのチアゾリジンジオン類の用途
NZ313874A (en) * 1995-08-10 2000-09-29 Warner Lambert Co Compounds used as medicaments useful in eliminating the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
AU725998B2 (en) * 1995-09-18 2000-10-26 Eisai R&D Management Co., Ltd. Treating NIDDM with RXR agonists

Also Published As

Publication number Publication date
AR015894A1 (es) 2001-05-30
CN1260715A (zh) 2000-07-19
DZ2521A1 (fr) 2003-02-08
BR9810444A (pt) 2000-09-05
EP0999837A1 (en) 2000-05-17
JP2002504138A (ja) 2002-02-05
EA004800B1 (ru) 2004-08-26
TW587937B (en) 2004-05-21
SK179399A3 (en) 2000-11-07
UY25050A1 (es) 2000-09-29
CN1133431C (zh) 2004-01-07
GB9712866D0 (en) 1997-08-20
PL343123A1 (en) 2001-07-30
ID23951A (id) 2000-06-08
NO996265L (no) 1999-12-17
HUP0003260A2 (hu) 2001-05-28
KR20010013843A (ko) 2001-02-26
ZA985237B (en) 2000-02-17
WO1998057636A1 (en) 1998-12-23
AP9901718A0 (en) 1999-12-31
UA70299C2 (en) 2004-10-15
HUP0003260A3 (en) 2001-12-28
AU8216398A (en) 1999-01-04
IL133143A0 (en) 2001-03-19
AR012997A1 (es) 2000-11-22
PE104499A1 (es) 2000-01-13
OA11517A (en) 2004-02-04
EA200000042A1 (ru) 2000-08-28
CA2294141A1 (en) 1998-12-23
IN189723B (enrdf_load_html_response) 2003-04-19
NO996265D0 (no) 1999-12-17
CO4940454A1 (es) 2000-07-24
AP1287A (en) 2004-06-26
MA26511A1 (fr) 2004-12-20
TR199903095T2 (xx) 2000-08-21

Similar Documents

Publication Publication Date Title
BG104060A (en) Diabetes treatment with thiazolyidindion and methformine
ZA977783B (en) Method of inhibiting fibrosis with a somatostatin agonist
BG104059A (en) Diabetes treatment with rosiglytazone and insulin
AU2373400A (en) Shelf-stable formulation of glucagon-like peptide-1
WO2000057900A3 (en) Factor for regulation of neurite growth
EP0647133A4 (en) COMPOSITIONS AND METHODS FOR IMPROVED DRUG DELIVERY.
AU2272097A (en) Drug delivery compositions suitable for intravenous injection
IL108611A0 (en) Prolonged delivery of peptides
MY129220A (en) "use of glp-1 analogs and derivatives administered peripherally in regulation of obesity"
IL160983A (en) Use of pyy for preparation of a medicament for modification of feeding behavior
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
BG104135A (en) Diabetes treatment with thiazolydindion, a form increasing the insulin and biguanide secretion
AU2911695A (en) Inplantable drug delivery pump
WO2000016797A3 (en) Use of glp-1 or analogs in treatment of stroke
WO2003018516A3 (en) Glucagon-like peptide-1 analogs
EP2016950A8 (en) Pharmaceutical composition comprising an exendin-4 peptide
EP1695983A3 (en) Glucagon-like peptide-1 analogs
ZA99104B (en) Method for administering ASPB28-human insulin.
LU91138I2 (fr) Glulisine d'insuline et ses dérivés pharmaceutiquement acceptables.
CA2284482A1 (en) Treatment of cardiomyopathy
AU4714393A (en) Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity
IL113566A0 (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
RU2000100346A (ru) Способы лечения ожирения
EP0683668A4 (en) PREPARATIONS AND METHODS FOR TRANSDERMAL DRUG ADMINISTRATION.
BG104062A (en) Treatment of diabetes with thiazolidindion, stimulant of insulin secretion and alpha-glucosidase inhibitor